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1. Introduction 
The term “vasculitis” includes a heterogeneous group of multisystemic disorders 
characterized pathologically by inflammation of blood vessels [1,2,3]. Inflammation can 
involve some, or all, of the thickness of the vessel wall. Immune complexes are a major 
component of vasculitis syndromes, and cellular mechanisms play a major pathogenic role 
in giant cell arteritis [4-12].  
Arterial lesion can lead to stenosis, occlusion, and ischemic infarction [1,13].  The diagnosis 
of vasculitis is difficult in most cases because of the insidious nature of the disease and the 
fact that various parts of the circulation can be affected without definitive signs or 
symptoms [1, 13-15]. More often than not, the diagnosis of vasculitis is made indirectly 
[1,15,16]. It is an infrequent disorder and a rare cause of stroke, even in young age groups 
[1,17-19]. Corticosteroid therapy is the basic and most common treatment for this disease, 
irrespective of the antigen involved or the type of vasculitis syndrome [1,4,5,8,20,21].   
The aim of this study was to use the Lausanne Stroke Registry (LSR) to evaluate how often 
vasculitis is a cause of first-ever stroke, and to determine the risk factors, clinical and 
radiological patterns, and early outcome for stroke with vasculitis. 
2. Patients and methods 
2.1 Patients 
The patients studied were those enrolled in the LSR [22] between January 1, 1980, and 
December 31, 1998. All patients were admitted to the Department of Neurology for first-ever 
stroke and were evaluated by at least one neurologist with stroke subspecialty training and 
by other specialists, depending on the accompanying symptoms (often a rheumatologist).  
All patients underwent a head CT or MRI, cardiac investigation (all by ECG, and, in most 
instances, by transthoracic or transesophageal echocardiography, with Holter ECG when 
needed), and Doppler investigation of the extracranial arteries. Serological or immunological 
testing was carried out when infection or immunological disease was suspected. Depending 
on need, patients also underwent cerebrospinal fluid (CSF) analysis and cerebral arteriography 
(including MRI angiography), while selected patients had a tissue biopsy. Patients with toxic 
vasculopathies were excluded due to the lack of clear-cut criteria for the differential diagnosis 
of pure vasculitis and drug–induced multiple vasospasm. 
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2.2 Methods 
Vasculitis was recognized on the basis of a comprehensive medical history and physical 
examination and the presence of vascular lesions in the CT or MRI with abnormalities in 
appropriate laboratory blood tests, and positive auto-antibodies or positive serological tests 
or bacteriological culture (blood and/or CSF) for infections. The criteria of the American 
College of Rheumatology were used to establish the correct diagnosis of vasculitis 
[1,4,13,16,20,23-25]. The diagnosis was confirmed by a characteristic vessel wall 
inflammatory reaction, with irregularities in the intracranial vessels on angiography in some 
cases. In all patients, other causes of stroke were first excluded. 
The functional status at 1 month after stroke onset (early outcome) was measured using a 5-
point scale, with 1 indicating no disability and 5 death. A good outcome was defined as 
patients with no or mild disability (points 1 and 2), while a bad outcome was defined as 
patients with moderate or severe disability, or death (points 3-5). 
2.3 Statistical methods 
Frequencies were compared using Fisher’s exact test for dichotomous factors or the chi-
squared test when more than 2 categories were present. Age differences were compared 
using Wilcoxon’s rank-sum test. 
3. Results 
Between January 1, 1980 and December 31, 1998, 27 of the 4,086 (0.7 %) patients in the LSR 
were found to have vasculitis, 15 (55.5 %) having primary vasculitis (PV) and 12 (44.5 %) 
secondary vasculitis (SV). The mean age of all stroke patients with vasculitis was 54.2 years, 
significantly lower than that of the 4,059 patients with stroke without vasculitis (mean age 
63.5 years, p= 0.02). The frequency of vasculitis in men and women was similar, being 0.76% 
and 0.5%, respectively (p=0.43). The 27 patients consisted of 11 men and 4 women with PV 
(male/female ratio 2.75; mean age, 61.3 years, range 20-81) and 8 men and 4 women with SV 
(male/female ratio 2.0; mean age, 45.3 years, range 22-81). Risk factors were found in 17 of 
the 27 patients (63%), of whom 11 had hypertension (41% vs 49% of patients without 
vasculitis; p=0.2) and 8 (29.6%) were active smokers. Other risk factors, which were rare, 
were only seen in single patients (see Tables 1 and 2). The early outcome in patients with 
vasculitis was similar to that in patients without vasculitis, a good outcome being seen in 
55.6% of patients with vasculitis and in 59% of patients without vasculitis (p=0.7).  
Tables 1 and 2 show the main characteristics of the patients with vasculitis. 
We would like to present GCA. 
4. Discussion 
Most authors have stated that vasculitis usually manifests as headache, meningeal signs, 
encephalopathy, psychiatric syndromes, dementia, cranial nerve palsies, and seizures, and 
only rarely as stroke [1,13,14,17]. There are also generally non-specific systemic symptoms, 
such as fever, fatigue and weight loss [19-21,25]. In our vasculitis patients, non-specific 
symptoms were most common, being present in 26 out of the 27 (96.3%). Meningeal signs 
were present in all 8 SV patients with infection. Headache-most typical sign for PACNS and 
GCA occurred in 15 patients (55%), but significant psychotic syndromes only in 2 (7.4%).   
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Characteristic PACNS
n = 6
GCA
n = 6
PAN 
n = 3 
Age, y  
(mean) 
20▲, 26, 43, 54, 67, 75▲ 
(47.5)
72°, 75°, 78°, 81°, 81°, 81° 
(78)
45◊, 55◊, 68° 
(56)
Sex 2 F, 4 M 1 F, 5 M 1 F, 2 M 
Risk factors, No patients 2 ac smok, 1 ac smok + hCh 1 diabetes+HY,  4 HY 3 HY 
Neurological 
disorders : 
  Hemiparesis 
  Aphasia 
  Hemianopsia 
  Cerebellar 
  Headache   
  Disturbances cons. 
  Epileptic seizure 
 Meningeal signs 
 
3 
1 
2 
6 
1 
2 
 
1
2 (with ataxia) 
 
 
4 
6 
1 
 
 
not
2 (1 with ataxia) 
1 
 
 
 
 
1 
 
not
Ictus territory : 
  Superficial 
  Subcortical 
  Brainstem/cerebellum 
  Multiple 
4 (MCA posterior reg) 
 
1 
1 (superficial)
3 (2 ACA super ant, 1 PCA 
reg) 
2            
1
 
2 (1 hemorrhagic) 
 
1 (deep) 
Arteriography, No 
patients 
 
5:
3-intracranial vessels 
irregularities 
1-intracranial vessels 
iirregularities 
   + 50% stenosis of SA 
1-sclerotic changes in both  
ICA▲
5:
3-arteriosclerotic changes in 
VAs 
2-arteriosclerotic changes in 
ICA 
 
 
2: normal view 
Outcome, disability
  None 
  Mild 
  Moderate 
  Severe 
  Death 
 
6 
1 
2 
2 
1 
1 
2 
Disease onset-to-stroke
Latency 
Coexisting symptoms 
Inaugural  (all patients)
 
fever (n=3), fatige (n=3) 
  
2 mo (n=1), 1mo (n=4),
inaugural (n=1) 
fatigue in all, polymyalgia 
(n=1) claudication of jaw 
(n=1),  
weight loss (n=2), fever 
(n=2),  amblyopia on one 
eye (n=1)
6 y, 3 y, 2 mo 
 
polyneuropathy in 
all, 
weight loss (n=2) 
fever (n=1) 
renal failure (n=1)  
Therapy, N patients 1-Dx+Antipl, 1-Antipl , 2-P,
1-P+CY,1-P+CY+FR 
1-MP followed by P,
5-P 
1-P,
1-MP followed byP, 
1-MP followed by 
P+CY 
PACNS=Primary angiitis of the central nervous system, GCA=Giant cell arteritis, PAN=Polyarteritis 
nodosa, ac smok=active smoking, F=female, M=male, HY=hypertension, hCh=hypercholesterolemia,  
MCA=medial cerebral artery, ACA=anterior cerebral artery, PCA=posterior cerebral artery, 
VAs=vertebral arteries, SA=subclavian artery, reg=region, super ant=superior anterior, 
cons=conciousness, , °=disease recognized before stroke, ▲=positive meningo-brain biopsy, y=years, 
mo=month, MP=methylprednisolone, P=prednisone, Dx=Dexamethason, CY=cyclophosphamide, 
FR=fraxiparin, Antipl=antiplatelet 
Table 1a. Clinical and neuroradiologic features, disease onset-to stroke latency, and current 
therapy for 15 patients with primary vasculitis 
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Laboratory investigations Type   of   Primary  Vasculitis 
PACNS  n = 6 GCA  n = 6 PAN  n = 3 
ESR mm/h 
 
<10 (n=4), 35, 40 5, 11, 15, 60, 70, 120 6, 68, 90 
CRP mg/l <10 (n=5), 73 
 
<10 (n=4), 30, 65 <10, 205, 253 
Immunological 
abnormalities 
in blood and in CSF  
ANA (1/320) 
IgG for EBV (n=1) 
IgG for: HS, EBV, Va 
(n=2) 
IgG 21.17(n:8.2-17) with rise 
of IgG Kappa and Lambda 
(n=1) 
 
ANA(1/80) 
+Antinucleoprotein 22 
+Anti-SSB 22 (n=1) 
ANCA  (1/320) and  
positive in CSF + 
ANA(1/80) 
+ IgG rise (n=1) 
 
Anticentriole Ab(1/8) 
+  
ANA positive (n=1) 
 
Immune complexes 
C1q 24% positive (n=1) 
Tissue biopsy (n patients) 2: granulomatous 
inflammations in a 
meningo-brain biopsy 
(fig.1) 
6: mononuclear and 
granulomatosus with 
multinucleated giant cells in 
TA 
(fig.2)  
3: focal segmental 
necrotizing vasculitis 
of small and medium 
sized arteries in liver 
and kidney (n=1) 
vasculitis signed and 
ischemic neuropathy 
in muscle-nerve 
biopsy (n=2) 
CSF: (n patients) 
Protein mg/l 
Cytosis cells/ml 
 blood-CSF barrier 
rupture  
(n = 3) 
7,920,  4,260,  295 
93 x 103 , 6.3,  1 
(n = 3) 
(n = 2) 
410, 250 
46 (32-polynuclear),   1 
(none) 
(n = 3) 
1.380, 355, 895 
32, 2, 2 
(n = 3) 
 
ESR=erythrocyte sedimentation, CRP=C reactive protein, E=erythrocytes, TA=temporal artery, 
CSF=cerebrospinal fluid, ANCA-perinuclear antineutrophil cytoplasmic antibodies, ANA=antinuclear 
antibodies, Ab=antibodies, EBV=Epstein-Baar virus, Va=varicella zoster, HS=herpes simplex  
 
Table 1b. Laboratory features for 15 primary vasculitis – associated strokes 
Our analysis confirmed the results of previous studies that vasculitis is a rare cause of 
stroke, since, out of the 4,086 patients with first-ever stroke, only 0.7% presented signs of 
vasculitis that could be a cause of the stroke. The mean age of the patients with vasculitis 
was significantly lower than that of stroke patients without vasculitis (54.2 vs 63.5 years, 
p=0.02). A good early outcome was seen at a similar frequency in patients with or without 
vasculitis (55.6% vs 59.0%). Ischemic stroke was more frequent than hemorrhagic stroke 
(96.3% vs 3.7%), but the group of patients with vasculitis was too small to allow a statistical 
conclusion to be drawn. The most common risk factor was hypertension, which occurred at 
a similar frequency in patients with or without vasculitis (41% vs 49%). The largest groups 
were patients with PACNS or Horton’s disease (GCA), with 6 cases in each group.  
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SLE=systemic lupus erythematosus, F=female, M=male, MCA=medial cerebral artery, PCA=posterio
cerebral artery, reg=region, post=posterior, ac smok=active smoking, , diab=diabetes , tc=tuberculoma, §
recognized before stroke,  mo = mouth, y=year, art=arthritis, oph=ophthalmic, MP=metylprednisol
Antipl=antiplatelet   
w
w
w
.intechopen.com
 
Advances in the Etiology, Pathogenesis and Pathology of Vasculitis 
 
368 
 
Table 2b. Laboratory features  for the 12 secondary vasculitis-associated strokes 
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The most significant manifestations of PACNS are reported to be headache or disturbances 
of consciousness [13,26-28]. All of our patients had headache, but only one showed 
disturbances of consciousness. The diagnosis of PACNS was proved histologically in 2 of 
our patients with typical granulomatous inflammation in a meningo-brain biopsy (fig.1); 
only one of the two underwent arteriography, which showed no significant sclerotic 
changes without irregularities of the intracranial vessels. In another 4 patients, the diagnosis 
was confirmed arteriographically (1 besides typical arterial irregularities also showed 
stenosis of the subclavian artery). This suggests that vasculitis and arteriosclerotic changes 
can coexist, which conflicts with the opinion of Woolfenden et al [23]. Many authors 
consider arteriography as a standard approach for patients suspected of vasculitis involving 
the cerebral vessels [14,23,29]. However, Vollner et al. [28] found that angiography reveals 
abnormalities in less than a third of PACNS patients, and these are often nonspecific. Many 
authors have reported that a good outcome is seen in many patients treated with 
prednisolone, but some have also reported a monophasic clinical course, usually with a 
benign outcome and not requiring aggressive immunosuppressive therapy [28,29]. A recent 
study shows similar results, as the early outcome was good in all our patients, one of whom 
did not receive glucocorticosteroids. 
 
 
Fig. 1. PACNS – Primary angiitis of the central nervous system. Granulomatosus 
inflammation in meningo-brain biopsy. 
In GCA, biopsy of the temporal artery is the principal means of making the diagnosis 
[1,2,4,12,13,30]. In all our patients, the diagnosis was confirmed histologically (fig.2). As in 
other reports [1,13], the outcome was good in most patients, but, in 1 patient, the early 
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outcome was bad, despite intensive corticotherapy similar patient describing by Staunton et 
al [31]. The condition of our patient deteriorated 3 days after starting therapy with 
prednisolone. The MRI showed a new ischemic lesion, and arteriography and Doppler 
investigation demonstrated occlusion of the ICA. Both Conn et al [32] and Reichart et al [19] 
have referred to the use of glucocorticoid therapy as a possible “double-edged sword” and 
suggested that progression of occlusion of the vessels may occur after control of 
inflammation.  All strokes in PAN [20,24] occurred while the illness was controlled by 
glucocorticosteroid therapy.   
 
 
Fig. 2. GCA – Giant cell arteritis. Granulomatosus with multinucleated giant cells in the wall 
of temporal artery 
Secondary vasculitis, which occurred in a very diverse group, was even rarer [1-4,8-
10,13,33,34].  The patients with SLE, sarcoidosis, or Behçet’s disease had recognized illness 
before the stroke and, when other causes of stroke were excluded, vasculitis was probably 
the cause of the cerebral ictus.  
Some of our patients presented vasculitis connected with various infections. In all these 
patients, the history and clinical and meningeal signs was very helpful in establishing the 
diagnosis. The patients with lues led a style of living which could predispose to 
transmission of this disease, the patient with borreliosis had erythema one year previously, 
which was overlooked at the time, and patients with zoster vasculitis had suffered from 
ophthalmic and otic zoster. The diagnosis of infectious vasculitis should be based on 
suitable serologic or bacteriologic investigations [6,7,11,37,38]. All of these patients 
presented inflammatory changes in the CSF (see Table 2 b). The interval between stroke and 
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the beginning of disease can be variable [7,38-40].  In the 3 lues cases, it was unknown and, 
in 1 tuberculosis patient, stroke disclosed the disease. 
To the best of our knowledge, there are no published data on a casual relationship between 
various types of vasculitis and first-ever stroke. The only reports we have been able to find 
focused on the relationship between individual types of vasculitis and stroke and case 
reports [5,6,10,14,19,23,25,27-31,33-40]. The results of our study indicate that various types of 
vasculitis can also be responsible for the first-ever brain infarction in elderly patients. In all 
vasculitis patients, the CT and MRI showed only non-specific brain infarcts, but, in 
tuberculotic vasculitis, specific signs, such as tuberculoma or hydrocephalus [11,38], were 
also sometimes seen. The presence of classic segmental narrowing in the cerebral angiogram 
suggests vasculitis [11,12,14,16,23,26] but was not seen in some cases. In agreement with 
published data [19,28], the presence of atherosclerotic changes did not exclude vasculitis as a 
cause of stroke in our patients. In GCA, the literature states that the definitive diagnostic 
investigation is biopsy of an affected artery [1,4,12,30], but cerebral biopsy, which can 
establish the diagnosis of PACNS, is not recommended in all cases [12,14-16,23]. 
5. Conclusions 
Our observations show that vasculitis is a rare cause of stroke. Vasculitis should be 
suspected in patients with first –ever stroke with previously recognized systemic 
autoimmune disease or presenting clinical and/or biological signs of autoimmune or 
infectious disease. The presence of atherosclerotic changes on the arteriogram does not 
exclude vasculitis. Recognition of vasculitis is often indirect after exclusion of other causes 
of stroke, while treatment depends on the disease type. Tissue biopsy is very helpful in 
establishing the diagnosis. Corticosteroid therapy does not protect patients against stroke.  
6. Abstract 
The aims of the study were to assess how frequently vasculitis is a cause of first-ever stroke 
and to assess risk factors, the clinical and radiological patterns in 4,086 patients from LSR.  
Methods: Vasculitis was recognized using the criteria of the American College of 
Rheumatology. Age differences were compared using Wilcoxon’s rank-sum test, frequencies 
-  Fisher’s exact  or the chi-squared test. Results: Vasculitis was found in 27 (0.7%) of stroke 
patients. The mean age of patients with vasculitis was significantly lower than   patients 
without vasculitis (54.2 vs 63.5 years; p=0.02). 63% patients with vasculitis had various risk 
factors, the most common being hypertension, with a similar frequency (41%) to that seen in 
patients without vasculitis (49%). A good early outcome was seen in 55.6% of the patients 
with vasculitis, similar to patients without vasculitis (59%; p=0.7).  Conclusion: Vasculitis is 
a rare cause of stroke. Corticosteroid therapy does not protect patients against stroke. 
Key words: Vasculitis - Angiitis – Stroke 
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accompanying figures and tables lucid and memorable. Here, you will find an amalgam between evidence-
based medicine to one based on eminence, through an exciting combination of original contributions,
structured reviews, overviews, state-of the-art articles, and even the proposal of novel pathogenetic models of
disease. The book contains contributions on the etiology and pathology of vasculitis, the potential role of
endothelial cells and cytokines in vascular damage and repair as well as summaries of the latest information
on several primary and secondary vasculitis syndromes. It also covers selected topics such as organ-specific
vasculitic involvement and quality of life issues in vasculitis. The editor and each of the authors invite you to
share this journey through one of the most exciting fields of the medicine, the world of Vasculitis.
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